TCRαβ-depleted progenitor cells

TCRαβ-depleted progenitor cells is an investigational cell therapy developed by St. Jude Children's Research Hospital for the treatment of high-risk hematologic malignancies in pediatric and young adult patients. This approach involves a haploidentical hematopoietic cell transplant (HCT) where the donor graft is selectively depleted of TCRαβ+ T cells and CD19+ B cells using immunomagnetic technology (e.g., CliniMACS). By removing TCRαβ+ T cells, the primary mediators of graft-versus-host disease (GVHD), while retaining γδ T cells and natural killer (NK) cells, the therapy aims to provide rapid immune protection and graft-versus-leukemia effects without the need for intensive post-transplant immunosuppression. The treatment protocol often incorporates a subsequent infusion of CD45RA-depleted memory T cells to accelerate immune reconstitution and may include prophylactic blinatumomab for B-cell malignancies.

Other names

TCRαβ-depleted haploidentical donor hematopoietic cell transplantationTCRαβ/CD19-depleted progenitor cellsTCRαβ-depleted progenitor cell graft